Business

Analysis:Investors set sights on Swiss franc for popular carry trades after yen intervention

Target is set to report earnings before the bell. Here's what to expect

Target is expected to report its fiscal second-quarter results Wednesday morning as the retailer offers a window into its turnaround progress.

AiMoGA Sees Auto-Robot Integration as Key to Growth

Zhang Guibing, President of AiMoGA Robotics, says the key to the company's strategy is integrating automotive and robotics platforms through both technology and supply chain capabilities. He speaks to David Ingles and Yvonne Man on…

Iran eyes military targets in Europe if Trump escalates war, insiders say

Proposals to retaliate against US assets beyond the Middle East come as many in Tehran see renewed conflict as inevitable

Venezuela abandons Nicolás Maduro to fate in US jail

Government makes no mention of freeing former leader after nearly two weeks of talks

Why Britain needs a Messi budget

The playing style of the great Argentine footballer demonstrates that less can be more

Chinese Coking Coal Futures Soar as Shanxi Supply Crunch Worsens

Chinese coking coal prices are surging as supply continues to tighten after the deadly accident in the mining hub of Shanxi three months ago.

Global food security may be collateral in Ukraine war

Moscow and Kyiv’s attacks on one another’s agricultural exports could result in a worldwide grain crisis

Remigration binds Maga to Europe’s far right

Once-taboo idea of mass expulsions returns to European nations after Trump embrace

America’s brands lose their magic

From mayonnaise to toothpaste, US household names are being undercut by own labels and outshone by insurgents

FTSE Defers Indonesia Stock Additions to Indexes Until December

FTSE Russell will defer certain index changes for Indonesian equities until at least its December review, giving it more time to assess the effectiveness of market reforms by local authorities.

Can weight-loss drugs lose their nasty side effects?

Pharma groups seek new generation of GLP-1 medicines as some patents start to expire